Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with different binding of glimepiride and glibenclamide to the 0-cell sulfonylurea receptor. Scatchard plot analysis of [3H]sulfonylurea binding to membranes isolated from rat 0-cell tumors and (RINm5F) insulinoma cells and to RINm5F cells demonstrated that glimepiride has a 2.5-3-fold lower affinity than glibenclamide. This corresponded well to the 8-9-fold higher kof f and 2.5-3-fold higher kon rates of glimepiride compared to glibenclamide as revealed by the dissociation and association kinetics of [3H]sulfonylurea binding and the K d values calculated thereof. In agreement, the concentrations required for half-maximal displacement of [3H]sulfonylurea bound to 0-cell membranes were significantly higher for glimepiride compared to glibenclamide. However, the binding affinity of glimepiride measured by both equilibrium binding and kinetic binding studies upon solubilization of 0-cell tumor membranes and RINm5F cell membranes increased up to the value for glibenclamide. This was primarily based on a drastic decrease of the dissociation rate constant of glimepiride whereas the kinetics of glibenclamide binding remained largely unaffected upon solubilization. These data suggest that the K d value alone is not sufficient for characterization of a suifonylurea drug, since the kinetic binding parameters may also determine its acute blood sugar lowering efficacy.
I. Introduction
Sulfonylurea drugs are widely used in the therapy of NIDDM. The initial hypoglycemic effect of oral sulfonylurea administration appears to rely on the acute stimulation of-the rate of insulin release from the pancreas (Yalow et al. [1] ). At the molecular level sulfonylureas are proposed to stimulate insulin secretion by binding to a receptor protein of the plasma membrane of pancreatic/3-cells (for reviews, see [2, 3] ). Receptor occupancy has been shown to inhibit K+-efflux via a plasma membrane ATP-regulated K+-chan -nel in islet cells [4] and E-cell lines such as RINm5F [5] or HIT T15 [6] . These channels also participate in the control of insulin release by glucose [7] via changes in the intracellular [ATP]/[ADP] ratio. Subsequent depolarization of the plasma membrane causes opening of voltage-dependent Ca2+-channels. The rise in intracellular Ca 2÷ triggers insulin release [8, 9] (for a review, see [10] ). This chain of events couples the insulin releasing effect and, thus, the primary hypoglycemic capacity of sulfonylureas via the plasma membrane electrical activity to their affinity to the/3-cell sulfonylurea binding sites which control the open/closed probability of the ATP-regulated K+-channel by unknown mechanisms.
Specific high-affinity binding sites (for a recent review, see Ashcroft and Ashcroft [11] ) have been characterized previously in /3-cell tumor membranes [12] [13] [14] , RINmSF cell membranes and intact RINm5F cells [15] , mouse pancreatic islet microsomes [16] , hamster insulin-secreting tumor cell (HIT T15) membranes [14, 17, 18] and intact HIT T15 cells [19] . In fact, a direct correlation has been found for the sulfonylureas studied so far between their dissociation constants for binding to/3-cell membranes and their ability to induce insulin secretion and to lower the blood sugar [5, 13, 16] . For instance, the second generation sulfonylurea, glibenclamide, is a 1000-fold more potent stimulator of insulin secretion than first generation compounds such as tolbutamide in correlation with the 1000-10 000-fold lower K d value of glibenclamide compared to tolbutamide [5] . Using the receptor occupancy theory, it was successful to predict the therapeutic blood concentrations and usual doses of sulfonylureas, based on the good correlation between plasma unbound concentration, insulin releasing potency and K d values [20] .
The novel sulfonylurea drug, glimepiride, is characterized by a 2-3-fold higher efficacy in diabetic patients compared to glibenclamide with respect to equivalence of the dose ranges leading to identical blood sugar levels after oral administration (Draeger, E., unpublished results). Here we studied whether glimepiride exhibits higher binding affinity to the fl-cell sulfonylurea receptor than glibenclamide and found that, in contradiction to this expectation, other (kinetic) binding parameters may explain the lower therapeutic doses required with glimepiride.
Parts of the results have been published in abstract form: Kramer [13, 21] . A 10 mM stock solution of glimepiride (made daily) was prepared by suspending 9.95 mg of glimepiride in 1.94 ml aqua bidest., subsequent supplementation of 60/zl of 1 M NaOH and warming up to 50-70°C. This solution was either added directly (up to 1 : 200 dilution) to the buffered assay mixtures containing membranes or cells. Radiolabeled sulfonylureas were diluted with 25 mM Hepes-KOH (pH 7.8). Scintillation cocktail ACS II was provided by Amersham-Buchler, Braunschweig, Germany. Collagenase, trypsin and proteinase inhibitors were from Boehringer, Mannheim, Germany. BSA (fraction V, radioimmunoassay grade), RPMI-1640 medium, fetal calf serum and antibiotics were obtained from Sigma, Deisenhofen, Germany. All other reagents (analytical grade) were provided from Merck, Darmstadt, Germany. Petri dishes and culture flasks were purchased from Nunc, Roskilde, Denmark. Glass fiber filters were from Whatman, Maidstone, UK. Nitrocellulose filters were bought from Millipore, Eschborn, Germany. Rats of the strain NEDH (New England Deaconess Hospital) were kindly donated by S. Warren.
Cell culture. RINm5F cells of the insulin-producing cell line, derived from a rat islet cell tumor [22, 23] , were grown in RPMI-1640 medium containing 10% (v/v) heat-inactivated fetal calf serum, 50 IU/ml penicillin, 0.25 /xg/ml fungizone and 50 ixg/ml streptomycin at 37°C in an atmosphere of humified air/CO 2 (19:1) according to Praz et al. [24] with the following modifications: The cells were seeded at a density of (2-4)" 104 cells/ml in 20 ml of medium (75 cm 2 culture flasks). The medium was replaced four times per week (one passage). Thereafter, the cells were treated with trypsin (0.02% trypsin in 0.9% NaC1/0.2 mM EDTA) for 2-5 min at 37°C. The trypsin-treated cells were diluted, reseeded at a density of 2" 10 6 cells per 75 cm 2 culture flask and grown to 70% confluency.
Preparation of RINmSF cell membranes. Cells from one culture flask were washed twice with ice-cold 25 mM Hepes-KOH (pH 7.4), 0.25 M sucrose, 0.5 mM EDTA, scraped with 20 ml of the same buffer and homogenized with 10 strokes of a tight fitting PotterElvehjem homogenizer followed by sonication (bath sonicator, 4°C, 10 s, maximal power). After centrifugation (200000 ×g, 45 min, 4°C), the pellet was suspended in 10 ml of 25 mM Hepes-KOH (pH 7.4), 0.25 M sucrose, 100 mM NaC1, 0.5 mM EDTA, 200 /xM PMSF and recentrifuged (1000 x g, 10 min). The supernatant was transferred to a new tube and centrifuged (50000 x g, 30 min, 4°C). The pellet was washed once with 25 mM Hepes-KOH (pH 7.4), 0.25 M sucrose and finally suspended in membrane buffer (25 mM Hepes-KOH (pH 7.4), 0.25 M sucrose, 150 mM NaC1, 1 mM EDTA, 100 /.LM PMSF, 10 /xg/ml soybean trypsin inhibitor, 10 /xM leupeptin, 10 /xM pepstatin, 20 /xg/ml E-64, 1 mM iodoacetamide) at 5 mg protein/ml. Aliquots were frozen in liquid N 2 and stored at -80°C.
Preparation of fl-cell tumor membranes. Non-malignant fl-cell adenoma tissue was dissected from rats of the strain NEDH after several transplantation cycles of the insulinoma when the tumor has grown up to a diameter of 2-3 cm as described previously (Geisen et al. [13] ), homogenized in 50 ml of buffer A (25 mM Hepes-KOH (pH 7.4), 0.25 M sucrose, 0.5 mM EDTA, 100 ~M PMSF) per g tissue in an Ultraturrax (3 × 5 s, max. power, on ice) and centrifuged (3000 × g, 5 min). The supernatant was transferred into new tubes and centrifuged (200000 ×g, 60 min, 4°C). The pellet was washed with 2 × 5 ml of buffer A, resuspended in 10 ml of buffer A per g tissue and centrifuged (75 000 × g, 30 min). The pellet was suspended in buffer A using a tight-fitting Dounce homogenizer.
Binding of sulfonylureas to [3-cell membranes . Filter binding assays were performed in a total volume of 1 ml containing the indicated amounts of protein, 25 mM Mops-KOH (pH 7.4), 0.1 mM CaC12 and 0.1-20 nM [3H]sulfonylurea. After incubation (25°C, 60 min for equilibrium conditions or periods indicated for kinetic experiments), the binding reactions were terminated by rapid filtration through Whatman GF/F filters soaked in the same buffer. The filters were washed with 3 × 5 ml of ice-cold 25 mM Hepes-KOH (pH 7.4), 100 mM NaCI, 1 mM EDTA, 200 /zM PMSF, 0.5 /zg/ml leupeptin, 0.75/zg/ml pepstatin and 2 × 5 ml of ice-cold Hepes-KOH (pH 7.4), placed in 10 ml of ACSII scintillation cocktail and after incubation overnight counted for radioactivity in a liquid scintillation counter. Nonspecific binding in parallel samples was determined in the presence of 1 /zM unlabeled ligand.
Binding of sulfonylureas to solubilized [3-cell membrane proteins. Isolated /3-cell tumor or RINm5F cell membranes were diluted with 25 mM Mops-KOH (pH 7.4), 100 mM NaC1, 0.1 mM CaCI 2, 200 ~zM PMSF, 0.5 /zg/ml leupeptin, 0.75 /xg/ml pepstatin, 50 /xg/ml antipain dihydrochloride, 1 /zg/ml aprotinin at 1 mg protein/ml and solubilized by addition of 1/10 vol. of 10% digitonin and subsequent incubation (30 min, 4°C) under gentle stirring. After centrifugation (200000 × g, 30 min, 4°C), indicated amounts of protein contained in the supernatant were incubated with radiolabeled ligand in a final volume of 1 ml (as described above). The binding reactions were terminated by the addition of 3 ml of ice-cold 15% PEG 8000, 25 mM Mops-KOH (pH 7.4), 100 mM NaCI, 0.5 mM EDTA, 200 /zM PMSF. After further incubation (15 min, 4°C), the mixtures were filtered through nitrocellulose filters (Millipore, HAWP, 0.22/xm) soaked with ice-cold 10% PEG 8000. The filters were washed successively with 5 ml ice-cold 10% PEG 8000 and 4× 5 ml 2% PEG 8000, dried, placed in 10 ml of ACSII scintillation cocktail and counted for radioactivity. Background radioactivity, which was measured by filtration of binding reactions lacking protein and accounted for up to 0.1% of the total radioactivity added, was subtracted from the total dpm values. Non-specific binding was determined in the presence of 1 /zM unlabeled ligand.
Binding of sulfonylureas to RINm5F cells. Cells seeded in 75 ml culture flasks at a density of 2.106 cells and grown to 70% confluency were treated with trypsin/EDTA (see above), washed with 3 × 10 ml Hepes-based Krebs-Ringer buffer containing 20 mM Hepes-KOH (pH 7.4), 125 mM NaCI, 5 mM KC1, 7.5 mM NaHCO 3, 2 mM CaCl 2, 0.8 mM MgSO 4 suspended at a density of 2-107 cells/ml in the same buffer and then incubated (4°C, 60 min for equilibrium Table 1. binding or periods indicated for kinetic studies) with 0.1-20 nM [3H]glimepiride or [3H]glibenclamide at a density of 4.106 cells per 0.5 ml assay volume. The incubation mixtures were rapidly filtered through Whatman GF/C filters soaked in ice-cold buffer under reduced pressure. Filtration and washing took less than 30 s. The filters were washed with 3 × 6 ml of ice-cold buffer containing 100/zM PMSF, 0.5/~g/ml leupeptin, 0.75 /xg/ml pepstatin, 1 /zg/ml aprotinin, 50 /zg antipain dihydrochloride, 20 /xg/ml E-64, dried, placed in 10 ml of ACSII scintillation cocktail and counted for radioactivity. Non-specific binding was determined in the presence of 1/xM unlabeled ligand.
Kinetic studies. For studying the association kinetics, the binding reactions (incubation conditions see above) were started by addition of radiolabeled ligand and terminated after the indicated periods by rapid filtration. For studying the dissociation kinetics, displacements of radiolabeled ligand bound at equilibrium (60 min incubation) were initiated by addition of unlabeled drug (final concn. 1 IzM) and terminated after the indicated periods. For termination, the incubation mixtures were rapidly chilled to 2-4°C by placing the assay tubes in a solid CO2/methanol bath for 1 s immediately prior to filtration in a filtration apparatus located in a cooled bench.
Miscellaneous. Protein was determined with the Amido black staining method (Popov et al. [25] ) using BSA as standard.
Results

Glimepiride exhibits lower binding affinity to el-cell membranes than glibenclamide
Specific binding of sulfonylurea drugs to isolated /3-cell tumor membranes, HIT T15 and RINm5F cell membranes has been attributed to high (K d = 0.1-1 nM) and low (K a = 100-400 nM) affinity binding sites [5, 6, [13] [14] [15] 17, 19, 26, 27] . The free plasma glibenclamide levels effective in insulin secretion (low nanomolar range) and the drug concentration required for halfmaximal stimulation of insulin release (~ 0.5 nM) from pancreatic islets [16] and insulin-secreting cell lines [5, 14] point to the high-affinity binding site as the only functional receptor, the occupancy of which ultimately leads to insulin secretion. The difference in the hypo- Scatchard plots derived from saturation experiments were curve-linear suggesting the existence of both highand low-affinity binding sites in /3-cell tumor membranes, RINm5F cell membranes and RINm5F cells (Fig. 1, Panels A-C) . Table 1 .
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sites are given in Table 1 . Thus, glimepiride is characterized by a 2.5-3-fold lower affinity to rat fl-cell tumor and RINm5F cell membranes as well as RINm5F cells compared to glibenclamide. The number of highaffinity binding sites is very similar for glimepiride and glibenclamide, but about 3-4-fold higher for B-cell tumor membranes compared to RINmSF membranes and RINm5F ceils (Table 1) .
Displacement of ligand binding confirms the ranking order of affinity for glimepiride and glibenclamide
To confirm the difference in affinity between glimepiride and glibenclamide, competition binding experiments were performed. Table 1 .
Glimepiride exhibits higher exchange rates for binding to B-cell membranes than glibenclamide
Next we asked the question whether the reduced affinity of glimepiride is based on lower association and/or higher dissociation rates of binding compared to glibenclamide. For studying the association kinetics (Fig. 3) , B-cell tumor membranes, RINmSF cell membranes and RINmSF cells were incubated with [3H]glimepiride and [3H]glibenclamide and, after the periods indicated, immediately chilled, filtered and counted for radioactivity. For studying the dissociation kinetics (Fig. 4) , the membranes and cells were preloaded with submaximal concentrations of [3H] sulfonylureas for 60 min at 25°C and 4°C, respectively. Displacement of radiolabel was initiated by addition of 1000-fold molar excess of unlabelel ligand.
[3H]Glimepiride or [3H]glibenclamide remaining bound after the indicated periods was determined by rapid filtration.
The time-courses revealed that glimepiride clearly associated with (Fig. 3 ) and dissociated from (Fig. 4 are given in Table 1 .
account for its higher dissociation constant compared to glibenclamide as measured by equilibrium binding. For this, the K d values were calculated as ratio between the dissociation and association rate constants. For calculation of the kon rate, the association reaction was treated as being pseudo-first order. Fig. 3 , Panel B displays the logarithmic plots of the ratio of ligand concentration bound to /3-cell tumor membranes (not shown for RINm5F cell membranes and RINm5F cells) under equilibrium conditions to the difference of the ligand concentration bound under equilibrium conditions and bound at each time point (t) versus time. Fig.  4 , Panel B displays the koff rates as the logarithmic plot of the ratio of ligand concentration bound at time (t) to that bound initially under equilibrium conditions versus time (not shown for RINm5F cell membranes and RINm5F cells). As expected from the respective half-life times, 2.5-3-fold higher association and 7-9-fold higher dissociation velocities were calculated for glimepiride compared to glibenclamide. The koff/kon ratios (Table 1 ) of glimepiride and glibenclamide for binding to fl-cell tumor membranes, RINm5F cell membranes and RINm5F cells are well in line with their K a values as determined by equilibrium binding. Thus, the lower binding affinity of glimepiride is explained by its binding kinetics. The logarithmic association and dissociation plots displayed non-linear curves. The biphasic nature of the time-courses which was more pronounced for glimepiride than for glibenclamide points to the occurrence of either heterogenous (high-and low-affinity) sulfonylurea binding sites or to cooperativity between two (or more) similar binding sites rather than to a bimolecular reaction involving only one type of binding centre (see Weiland et al. [28] for a discussion of binding kinetics).
Solubilization of [3-cell membranes alters the binding characteristics of the glimepiride-binding sites
So far it is unknown from which side of the /3-cell plasma membrane sulfonylureas gain access to their high-affinity binding sites and whether the drugs interact with the receptor from the aqueous environment or from the lipid bilayer after lateral movement in the plane of the membrane. The accessibility of the receptor for sulfonylureas may determine in part their binding characteristics and explain differences herein between drugs of different lipophilicity as is the case for glimepiride and glibenclamide. Therefore, we finally studied the influence of the membrane environment on the K d values and kinetic binding parameters of glimepiride and glibenclamide. To allow measurement of specific [3H]sulfonylurea binding to detergentsolubilized membrane proteins, the filtration assay was modified by precipitation of the total incubation mixtures with PEG in the cold prior to filtration over sulfonylurea specifically bound to solubilized/3-cell tumor membrane proteins using the modified procedure. In contrast to/3-cell tumor membranes, RINm5F cell membranes and RINm5F cells, low-affinity binding sites for both sulfonylureas were barely detectable upon solubilization of /3-cell tumor membranes. Similar observations were made previously by Niki et al. [29] for HIT T15 cell membranes.
The Scatchard plot analysis shows that solubilization by digitonin did only marginally affect the binding parameters for glibenclamide (Fig. 5 compared to Fig.  1 ). In contrast, glimepiride exhibited a 2.5-3-fold higher affinity to solubilized fl-cell tumor membrane proteins compared to membranes. This was also reflected in the g d values calculated as koff/kon ratios from association and dissociation experiments (Table 1 ). This rise in affinity upon solubilization was based mainly on the ~ 4.5-fold reduction of the kof f rate constant for glimepiride (Fig. 6 , Panels A and B) whereas the kon rate constant decreased only ~ 0.7-fold (Fig. 6 , Panels C and D) compared to the value for membranes. In marked contrast, the kof f and kon rate constants for glibenclamide were only marginally affected upon solubilization of /3-cell membranes (Fig. 6 and Table 1 ). Consequently, the affinity of glimepiride to solubilized /3-cell membranes was only slightly lower than of glibenclamide. This was corroborated by the lower concentrations of glimepiride but not of glibenclamide which were required for displacement of [3H]glimepiride bound to solubilized /3-cell tumor (Fig. 7 , Panel A) and RINmSF cell (Panel B) membrane proteins compared to the respective membranes (see Fig. 2 ). As a result, the ICs0 values of glimepiride for inhibition of [3H]glimepiride binding to the solubilized receptor decreased up to the values of glibenclamide for the solubilized as well as membrane-embedded receptor (Table 1) .
Discussion
The present data strongly suggest that the lower binding affinity of glimepiride to //-cell membranes relies at least in part on the membrane environment of the sulfonylurea receptor. However, this does not exclude the possibility that glimepiride and glibenclamide actually bind to different receptor proteins which display different binding characteristics when embedded within the fl-cell membrane. Elucidation of this point will require identification of the binding proteins, e.g., by means of photoaffinity labeling (Kramer et al. [30] ; see accompanying paper [31] ).
The physiological relevance of the higher exchange rate (i.e., higher association and dissociation velocities) of glimepiride with its receptor protein as well as of its lower binding affinity compared to glibenclamide remains a matter of speculation. (i) The initial decrease of the blood sugar levels in dogs, rats and rabbits is more pronounced after oral and intravenous administration of clear sodium salt solutions of glimepiride compared to, glibenclamide [21] . The rapid-onset blood glucose lowering activity of glimepiride may be due to a more rapid direct insulinotropic effect upon the islet of Langerhans. In agreement with this hypothesis, it was found that in the perifused rat pancreatic islets and in the isolated perfused rat pancreas, glimepiride released insulin more rapidly and more effectively than glibenclamide (Geisen, K., unpublished results). This may be related to the 3-fold higher kon rate of glimepiride binding to /3-cell membranes. However, with respect to the blood sugar lowering profile, it is difficult to dissect differences in kinetic binding parameters from different pharmacokinetic behaviour of the two drugs.
(ii) The prolonged decline of plasma glucose levels provoked by a single oral dose of glimepiride compared to glibenclamide in dogs and rabbits (Geisen [21] ) may be explained by the 3-fold higher exchange rate of glimepiride bound to the sulfonylurea receptor if desensitization of the insulin releasing mechanism is induced by occupancy of the sulfonylurea receptor with a drug (exhibiting a lower exchange rate). Desensitization of receptor mediated processes by permanent binding of the ligand to its receptor involving distinct molecular mechanisms is well established for several hormone signaling pathways, i.e., /3-adrenergic receptors (for a review, see Benovic et al. [32] ). In this respect, it is interesting that internalization of glibenclamide has been reported for HIT T15 cells (Carpentier et ah [33] ). If this based on endocytosis of the sulfonylurea receptor when occupied by the ligand, it may represent a mechanism for desensitization by down regulation of the number of sulfonylurea receptors at the cell surface which will be more pronounced for sulfonylureas with lower exchange rate. However, the long term hypoglycemic activity of sulfonylureas, in general, and of glimepiride, in special, may involve so-called extra-pancreatic sites of action, in addition (Kolterman et al. [34] ; Mi]ller et ah [35] ; for a review, see Gerich [36] ). (iii) The higher K d value of glimepiride compared to glibenclamide may be responsible for the lower total decline of the blood sugar in the dog (Geisen [21] ). Clearly, these features would represent significant therapeutical benefits for NIDDM patients.
